Mass Tort brief
The Tylenol Litigation Rebound
An appeals court revives over 500 acetaminophen lawsuits, putting billions of dollars in potential liabilities back on the table.
Signalpoint TeamBrief
Mass Tort
By narrowing judicial power to screen out expert science, the court handed families their leverage back — leaving Kenvue to face juries or negotiate a multi-billion-dollar settlement.
BackgroundMultidistrict litigation consolidates similar personal injury lawsuits before a single federal judge to streamline pretrial proceedings. Federal Rule of Evidence 702 governs whether expert scientific testimony is reliable enough to be presented to a jury.
Points
- The appellate panel ruled that the district court exceeded its judicial discretion by prematurely acting as a jury, which improperly barred families from presenting their scientific case.
- The decision rejected Kenvue’s federal preemption defense, confirming that federal drug labeling regulations do not prevent manufacturers from adding voluntary warning labels to their packaging.
- Families are suing Tylenol maker Kenvue and retail giants like Walmart, claiming the companies failed to warn expectant mothers about the potential neurodevelopmental risks of acetaminophen.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.